Gennova Bio joins CEPI to develop vax against Nipah virus

Gennova Biopharmaceuticals, in partnership with CEPI, will advance the development of a self-amplifying mRNA vaccine against Nipah virus with a $13.38 million funding. They will collaborate with the Houston Methodist Research Institute to utilize AI technology for optimizing virus-derived proteins to enhance vaccine targets.